About: AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $12.63 (-0.79%)
ABCL NASDAQ Abcellera Biologics Inc
Abcellera Biologics Inc share price
ABCL price activity
Last Price
$12.630
Change (24hr)
-0.10 USD (-0.79%)
Volume
5.41M
Volume (4w avg)
-
Open
$12.73
Day Range
$12.37 - $12.96
Previous Close
$12.73
Last Trade
18 Sep, 8:22 pm GMT+0
Delayed
18 Sep, 8:22 pm GMT+0
ABCL price performance
Delayed
18 Sep, 8:22 pm GMT+0
ABCL Market Signals